Loading
Ceralasertib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for non-small-cell lung cancer, melanoma and triple-negative breast cancer, aimed at ATR.
Ceralasertib (AZD6738) is a small-molecule drug developed by AstraZeneca. Its target is ATR (the sponsor names ATR (Ataxia Telangiectasia and Rad3-related) kinase). The sponsor states: Ceralasertib is an oral small-molecule ATR kinase inhibitor, tested here in combination with the PD-L1 inhibitor durvalumab; the CT.gov record's exclusion criterion barring prior ATR inhibitor use is consistent with this. ClinicalTrials.gov describes the intervention as: Participants will receive oral tablet of ceralasertib as stated in arm description. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy), in non-small-cell lung cancer, melanoma and triple-negative breast cancer. The largest, NCT05450692, plans to enrol 594 participants (actual) with primary completion was scheduled for 2025-10-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ceralasertib is an oral small-molecule ATR kinase inhibitor, tested here in combination with the PD-L1 inhibitor durvalumab; the CT.gov record's exclusion criterion barring prior ATR inhibitor use is consistent with this. Connects to ATR.
1.Ceralasertib slips into a pocket on ATR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ceralasertib" OR ABSTRACT:"Ceralasertib" OR TITLE:"AZD6738" OR ABSTRACT:"AZD6738") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ceralasertib, not a curated reading list.
Shares Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy, AstraZeneca, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.